Oxford BioMedica, Bioverativ to Develop Lentiviral Vectors for Hemophilia Gene Therapy

05:41 EST 15 Feb 2018 | Genetic Engineering News

Oxford BioMedica said today it will partner with Bioverativ to develop and manufacture lentiviral vectors designed to treat hemophilia, through a collaboration that could generate up to $105 million-plus for Oxford BioMedica. Bioverativ—which is being acquired by Sanofi for approximately $11.6 billion —has agreed to license Oxford BioMedica’s LentiVector ® Enabled technology, as well as its industrial-scale manufacturing technology. LentiVector is a lentiviral-based gene delivery system designed to overcome safety and delivery challenges associated with earlier-generation vectors. According to Oxford BioMedica, the platform’s advantages include large therapeutic payloads (up to 9 kb), permanent modification of dividing and nondividing cells, and no pre-existing immunity The platform can also integrate genes into nondividing cells, including in the brain and retina, with the company citing long-term studies suggesting gene expression may be maintained indefinitely—offering the prospect of permanent therapeutic benefit following a single administration. LentiVector is also a ...

Original Article: Oxford BioMedica, Bioverativ to Develop Lentiviral Vectors for Hemophilia Gene Therapy


More From BioPortfolio on "Oxford BioMedica, Bioverativ to Develop Lentiviral Vectors for Hemophilia Gene Therapy"

Quick Search


Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...